Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Rating of “Hold” from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned an average rating of “Hold” from the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $4.79.

MRNS has been the subject of a number of analyst reports. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Finally, Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Monday, September 23rd.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of MRNS. abrdn plc increased its holdings in shares of Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares during the period. Suvretta Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the period. Franklin Resources Inc. lifted its stake in shares of Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the period. GSA Capital Partners LLP increased its stake in shares of Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $813,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.53 on Wednesday. The company’s fifty day moving average price is $0.33 and its two-hundred day moving average price is $1.03. The firm has a market capitalization of $29.43 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $11.26.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.